Mei‐Ling Han
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria 38
- Microbiology top 2%
- Antimicrobial Peptides and Activities 6
- Endocrinology top 5%
- Vibrio bacteria research studies 8
- Pharmacology top 5%
- Antibiotics Pharmacokinetics and Efficacy 21
-
- Tuberculosis Research and Epidemiology 9
-
- Pneumocystis jirovecii pneumonia detection and treatment 7
-
- Bacteriophages and microbial interactions 7
-
- Bacterial Genetics and Biotechnology 5
Mei‐Ling Han
63 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 118
- Molecular Medicine 673
- Microbiology 241
- Applied Microbiology and Biotechnology 68
- Endocrinology 146
- Pharmacology 309
Countries citing papers authored by Mei‐Ling Han
This map shows the geographic impact of Mei‐Ling Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Ling Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Ling Han more than expected).
Fields of papers citing papers by Mei‐Ling Han
This network shows the impact of papers produced by Mei‐Ling Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Ling Han. The network helps show where Mei‐Ling Han may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mei‐Ling Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 11 | |
| 7 | 2023 | 16 | |
| 8 | 2022 | 10 | |
| 9 | 2022 | 47 | |
| 10 | 2020 | 12 | |
| 11 | 2020 | 8 | |
| 12 | 2020 | 39 | |
| 13 | 2020 | 32 | |
| 14 | 2019 | 20 | |
| 15 | 2018 | 10 | |
| 16 | 2018 | 15 | |
| 17 | 2017 | 15 | |
| 18 | 2017 | 15 | |
| 19 | 2016 | 110 | |
| 20 | 2016 | 34 |
About Mei‐Ling Han
Mei‐Ling Han is a scholar working on Molecular Medicine, Microbiology and Endocrinology, having authored 67 papers that have together received 1.8k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (38 papers), Antibiotics Pharmacokinetics and Efficacy (21 papers), Tuberculosis Research and Epidemiology (9 papers), Vibrio bacteria research studies (8 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers), Bacteriophages and microbial interactions (7 papers), Antimicrobial Peptides and Activities (6 papers) and Bacterial Genetics and Biotechnology (5 papers). The work is most often cited by research in Molecular Medicine (673 citations), Microbiology (241 citations) and Applied Microbiology and Biotechnology (68 citations). Mei‐Ling Han has collaborated with scholars based in Australia, United States and China. Frequent co-authors include Jian Li, Tony Velkov, Yan Zhu, Jian‐Min Yue, Darren J. Creek, Yu‐Wei Lin, Seong Hoong Chow, Hsin‐Hui Shen, Zhong‐Qin Liang and Long Wang. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, ACS Infectious Diseases, Journal of Natural Products, Journal of Antimicrobial Chemotherapy and International Journal of Antimicrobial Agents.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.